The VenaSeal (Medtronic, Minneapolis, Minn) cyanoacrylate closure system is a nonthermal technique for ablating saphenous veins using a proprietary n-butyl cyanoacrylate. One possible side effect is an allergic reaction to cyanoacrylate. We report the case of a 49-year-old woman treated with cyanoacrylate closure who developed a persistent type IV hypersensitivity reaction. The patient elected to have the vein excised, and the histologic features were consistent with a type IV hypersensitivity reaction. VenaSeal (Medtronic, Minneapolis, Minn) cyanoacrylate closure (CAC) system is a novel technique for ablating saphenous veins using a proprietary n-butyl cyanoacrylate (CA) that polymerizes quickly on contact with blood.
VenaSeal (Medtronic, Minneapolis, Minn) cyanoacrylate closure (CAC) system is a novel technique for ablating saphenous veins using a proprietary n-butyl cyanoacrylate (CA) that polymerizes quickly on contact with blood. 1 The purpose of this report was to detail the clinical course of a patient who developed a type IV hypersensitivity to CA after endovenous treatment of the great saphenous vein (GSV) for venous insufficiency. The patient provided written consent for use of images and written descriptions of the case for academic purposes.
CASE REPORT
A 49-year-old woman presented for evaluation of persistent ache, tiredness, and swelling in the left leg (Clinical, Etiology, Anatomy, and Pathophysiology class 3; Venous Clinical Severity Score, 7). Venous duplex ultrasound imaging of the left leg demonstrated GSV reflux and numerous branch varicosities. The patient reported a history of allergy to sulfa and penicillin but denied any allergy to CA or adhesives.
The patient elected CAC of the left GSV with 1.3 mL of adhesive used to occlude the GSV from 5 cm distal to the saphenofemoral junction to the proximal calf. In addition, 3 mL of 1% sodium tetradecyl sulfate was injected into the branch veins in multiple injections remote from the GSV CAC in the associated branch varicosities.
On postoperative day (POD) 7, the patient was without complaints, and the ultrasound examination showed that the left GSV was occluded from 2 cm distal from the saphenofemoral junction to the vein access point in the proximal calf. On POD 13, she returned, complaining of leg pain and redness. This was thought to be either phlebitis or an allergic reaction and was treated with oral diphenhydramine (Benadryl) and topical diclofenac (Voltaren) 1% cream. On POD 17, she complained of progressive leg pain, chills, and erythema over the medial thigh.
Because of concern about infection, she was treated with cephalexin (Keflex) for 5 days. On POD 21, she described significant improvement in symptoms. On POD 124, she returned, complaining of persistent leg pain, erythema, and swelling. She Immunohistochemical stain showed that a majority of the mononuclear cells were T lymphocytes, and most of these were of the T4 subset (Fig 2) .
DISCUSSION
CAC was approved by the Food and Drug Administration in 2015 to treat saphenous vein reflux in patients with venous insufficiency. First-in-human studies did not report hypersensitivity reactions. 2, 3 In the VenaSeal Sapheon Closure System Pivotal Study (VeClose), none of the 114 subjects randomized to CAC developed cutaneous or deep tissue hypersensitivity reactions. 4 As with many new medical devices, more is learned in the In the Lake Washington Vascular VenaSeal Post-Market Evaluation (WAVES) trial, one patient developed fullbody urticaria 1 week after the CAC procedure, which resolved after treatment with oral steroids. 5 Park et al 6 described a phenomenon they termed phlebitis-like abnormal reaction in 25% of patients treated with VenaSeal, which they speculated to be a type IV hypersensitivity reaction. This percentage, however, is far higher than what has otherwise been reported in published studies and is not consistent with what we see in our practice, suggesting the need to more clearly define this condition and to track its incidence in future studies.
In preclinical studies, the main histopathologic manifestation at 3 days to 2 weeks was an acute inflammatory reaction; this progressed to subacute vasculitis at 3 weeks, and a chronic granulomatous foreign body reaction developed at 4 weeks. 7 In chronic preparations, the vessel had fibrotic changes with partial vascular recanalization. 8, 9 By 60 days, histologic changes were consistent with a chronic foreign body-type inflammatory response.
In this case, the histopathologic evaluation showed intravascular foreign body material with nonspecific inflammation. The findings were not diagnostic of primary vasculitis or infection and suggested the possibility of an immune reaction that targeted the luminal contents or lumen-exposed endothelial or subendothelial tissue. The predominant cell type was T4, with additional nonspecific inflammatory markers consistent with a hypersensitivity reaction.
Cutaneous allergic reactions to CA are well described as type IV hypersensitivity reactions. Type IV hypersensitivity reactions have occurred with topical medical uses of CA, such as Dermabond (Ethicon, Somerville, NJ) for skin closure, and adhesives used for glucose sensor and eyelash extensions and artificial nails. [10] [11] [12] Type IV hypersensitivity reactions are not antibody mediated, like the other hypersensitivity reactions, but rather are a T lymphocytemediated response to a recognized foreign antigen. The true incidence and severity of type IV hypersensitivity reactions to CAC are unknown. The manufacturer (Medtronic) has reported in a personal communication with the authors that the observed rate of hypersensitivity reaction resulting in explantation of the treated vein is <1 in 10,000 to date.
Our protocol is to screen patients for allergies in general and known hypersensitivity reactions to adhesives and CA. We take efforts to prevent extravascular CAC from the vein when the catheter is removed from the entry point by "sheathing" the treatment catheter while the sheath is withdrawn through the skin to avoid subcutaneous and dermal CA exposure. Postoperatively, we ask that patients about itching at the treatment site, which may help distinguish a hypersensitivity reaction from phlebitis. If a patient develops a suspected hypersensitivity, we first treat it with topical steroids, followed by oral steroids and antihistamines. If the reaction persists, we refer the patient for hypersensitivity testing to confirm a specific reaction to CAC.
Further postmarket studies are needed to explore the possible role of preoperative CA patch testing. At this time, however, there is insufficient evidence to recommend routine patch test screening before CAC use. Studies are also needed to help define a medical regimen that can optimally treat the symptoms as well as the timing of initiation of such an approach. The best approaches to avoid this complication are likely to be adequate screening of patients and informing them of the risks before the procedures. Patients should be asked about a history of allergic reactions to CA. This includes CA issued in the home, at work, with cosmetic applications, or for previous skin closure. 5 Patients who might be considered at higher risk of having or developing allergic sensitization to CAC, nail care industry workers, for example, should be informed of the presence of CA in this closure system and be offered alternative forms of treatment. 13 
CONCLUSIONS
Type IV hypersensitivity reactions to CA are a potential complication of treatment. The treating provider should be aware of this potential complication when selecting patients for this therapy.
